Novo Nordisk ASMEX:NVON -0.60%76 Days Payable is 969.72 as of Mar. 2026, which is 681% above its 10-year median of 124.19. GuruFocus rates MEX:NVON with a GF Score™ of 76/100 and a GF Value™ of MXN2,387.52 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Novo Nordisk AS ranks better than 94.37% on this metric.
The historical rank and industry rank for Novo Nordisk AS's Days Payable or its related term are showing as below:
MEX:NVON'
s Days Payable Range Over the Past 10 Years
Min: 105.28 Med: 124.19 Max: 945.9
Current: 440.29
During the past 13 years, Novo Nordisk AS's highest Days Payable was 945.90. The lowest was 105.28. And the median was 124.19.
MEX:NVON's Days Payable is ranked better than 94.37% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs MEX:NVON: 440.29
Novo Nordisk AS's Days Payable
increased
from Mar. 2025 (599.18) to Mar. 2026 (969.72).
It may suggest that Novo Nordisk ASdelayed paying its suppliers.
Novo Nordisk AS Days Payable Related Terms
Novo Nordisk AS Days Payable Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVON vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Novo Nordisk AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NVON) has a Days Payable of 969.72 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novo Nordisk AS and its competitors. This is 681% above median its historical median of 124.19. Over the past decade, Novo Nordisk AS's Days Payable has ranged from 105.28 to 945.90. According to the industry distribution chart, Novo Nordisk AS ranks #52 out of 923 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Novo Nordisk AS's Days Payable too high?
Novo Nordisk AS's current Days Payable of 969.72 is 681% above median its 10-year median of 124.19. Over the past 10 years, this metric has ranged from a low of 105.28 to a high of 945.90. The Drug Manufacturers industry median Days Payable is 90.98. Novo Nordisk AS's value of 969.72 is 965.9% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #52 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #52 out of 923 companies for Days Payable. This places Novo Nordisk AS in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Novo Nordisk AS's value of 969.72 is 965.9% above this benchmark. Historically, Novo Nordisk AS's own Days Payable has ranged from 105.28 to 945.90 over the past decade. While the company's 10-year median is 124.19 vs. the industry median of 90.98, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Days Payable of 969.72 is 965.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Days Payable is 969.72, which is 681% above median its own 10-year median of 124.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NVON) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.52, compared to a current price of MXN831.50 — trading 65.2% below its estimated fair value. The current Days Payable is 969.72, which is 681% above median its 10-year median of 124.19 and 965.9% above the Drug Manufacturers industry median of 90.98. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NVON), the current Days Payable is 969.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NVON) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN831.50 is trading 65.2% below its estimated GF Value™ of MXN2,387.52.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NVON:
Days Payable: 969.72 (681% above median its 10-year median of 124.19)
GF Value™: MXN2,387.52 vs. price of MXN831.50 (65.2% below fair value)
Industry Position: 965.9% above the Drug Manufacturers median (#52 of 923)
No single metric tells the full story. See the MEX:NVON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score
Get the complete analysis for MEX:NVON
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVON has been successfully added to your 
